Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma 2Sarcoma, Synovial 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PRETEXT I Hepatoblastoma 1Osteosarcoma 1Neurofibrosarcoma 1Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1Localized Extraskeletal Ewing Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Central Nervous System Neoplasms 1

Interventions

sargramostim 3dinutuximab 3Vincristine 3Topotecan 3Stem Cell Transplantation 3Radiation 3Platinum 3Melphalan 3Isotretinoin 3Doxorubicin 3Cyclophosphamide 3Congresses as Topic 3Colony-Stimulating Factors 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3Temozolomide 2Irinotecan 2Etoposide 2Busulfan 23-Iodobenzylguanidine 2temsirolimus 1etoposide phosphate 1Thiotepa 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Peripheral Blood Stem Cell Transplantation 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ganglioneuroblastoma × Razoxane × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡